Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion received a recommendation for marketing authorization from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) for CT-P42, a biosimilar referencing Eylea, across 30 European countries for four indications including neovascular (wet) age-related macular degeneration.
📊 Key Disclosure Content & Financial Highlights
- Overview
- Company: Celltrion, Inc. (Stock Code: 068270)
- Disclosure Type: Major Matters Report Related to Investment Decisions
- Subject: CHMP Recommendation for Marketing Authorization for CT-P42 (Eylea Biosimilar)
- Reviewing Authority: Committee for Medicinal Products for Human Use (CHMP) under European Medicines Agency (EMA)
- Key Dates (Local Time): Application Date 2023-11-23 / Recommendation Date 2024-12-12
- Confirmation Date: 2024-12-15 (Date CHMP recommendation was confirmed)
- Product & Indication Details
- Product: Eylea Biosimilar CT-P42 (Active Ingredient: Aflibercept)
- Target Territory: 30 European Countries
- Recommended Indications:
- Neovascular (wet) age-related macular degeneration (AMD)
- Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
- Visual impairment due to diabetic macular oedema (DME)
- Visual impairment due to myopic choroidal neovascularisation (myopic CNV)
- Key Details & Future Plans
- Recommendation Scope: Secured positive recommendation across the target indications in 30 European countries
- Expected Effects: Expected to provide treatment options to more patients in the future by securing marketing authorization recommendation
- Future Plans: Expects to obtain final marketing authorization from the European Commission (EC) in the near future following the CHMP recommendation
- Additional Notes: Content will be utilized in upcoming press releases and IR materials
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of European Commission (EC) Final Marketing Authorization
This disclosure serves as official notification regarding the CHMP recommendation for CT-P42 across 30 European countries. Following the CHMP recommendation, the final marketing authorization decision will be made by the European Commission (EC). Therefore, monitoring subsequent disclosures regarding final EC approval is important. Relevant updates can be confirmed through future disclosures or official IR materials.
📢 Disclaimer & Source Notice
Source: This content was structured and generated based on official disclosure data from the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
